
Repatha for 18 months reduced non-calcified plaque on CT angiography in a 47-patient study
In a small imaging study, intensive LDL lowering with the PCSK9 inhibitor evolocumab (average LDL about 30 mg/dL) shrank non-calcified plaque while total plaque volume was unchanged. Louis compares this with the roughly 5 uL/year soft plaque growth in people untreated at risk.


